Long‐term treatment with the oncolytic ECHO‐7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient‐three case reports
Pēteris Alberts(Maxygen (United States)), Dite Venskus, Jurijs Nazarovs(Pauls Stradiņš Clinical University Hospital), Guna Proboka(Creative Commons), Sergejs Isajevs(Riga East University Hospital), Linda Brokāne, Romualds Erdmanis, Evija Olmane(Pauls Stradiņš Clinical University Hospital), Kārlis Kupčs(Pauls Stradiņš Clinical University Hospital), Zanda Krastiņa(Pauls Stradiņš Clinical University Hospital), Māra Romanovska(Pauls Stradiņš Clinical University Hospital)
Cited by 54
Related Papers
Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains
|Endocrinology|2003|263
Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice
|Diabetologia|2002|259
Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1
|Journal of Medicinal Chemistry|2002|211
The advent of oncolytic virotherapy in oncology: The Rigvir® story
|European Journal of Pharmacology|2018|179